Skip to main content

News & Media

Total 11
Number Title Author Date Votes Views
11
펠레메드, ‘FLT3 저해제’ AML 美1상 “FDA IND 승인”
관리자 | 2024.06.19 | Votes 0 | Views 1437
관리자 2024.06.19 0 1437
10
펠레메드, ‘YAP-TEAD 저해제’ 특허 출원
관리자 | 2024.02.14 | Votes 0 | Views 1462
관리자 2024.02.14 0 1462
9
펠레메드, ‘FLT3 저해제’ 조스파타 저항성모델서 “효능”
yckim83 | 2024.02.07 | Votes 0 | Views 1342
yckim83 2024.02.07 0 1342
8
펠레메드, ‘FLT3 저항성 타깃’ AML 전임상 “AACR 발표”
yckim83 | 2023.05.15 | Votes 0 | Views 1735
yckim83 2023.05.15 0 1735
7
펠레메드, 급성골수성백혈병치료제 등 혁신신약 후보물질 파이프라인 개발 박차
yckim83 | 2023.05.15 | Votes 0 | Views 1661
yckim83 2023.05.15 0 1661
6
펠레메드, 시리즈A 브릿지 55억..“FLT3 항암제 전임상”
yckim83 | 2023.03.22 | Votes 0 | Views 1604
yckim83 2023.03.22 0 1604
5
펠레메드, 중기부 아기유니콘200 육성기업 선정
user | 2022.06.17 | Votes 0 | Views 1599
user 2022.06.17 0 1599
4
펠레메드, ‘FLT3/RET 이중저해제’ AML “ASCO 발표”
user | 2022.05.24 | Votes 0 | Views 1717
user 2022.05.24 0 1717
3
펠레메드, 저분자화합물 발굴 ‘펠레셀렉트’ 장점은?
user | 2021.08.23 | Votes 0 | Views 1898
user 2021.08.23 0 1898
2
“내성 위험 확 줄인 표적 항암신약 조만간 내놓을 것”
user | 2021.01.20 | Votes 0 | Views 1298
user 2021.01.20 0 1298